Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) represents a common cancer worldwide. Past therapeutic advances have not significantly improved HNSCC prognosis. Therefore, it is necessary to further stratify HNSCC, especially with recent advances in tumor immunology. Methods: Tissue microarrays were assembled from tumor tissue samples and were complemented with comprehensive clinicopathological data of n = 419 patients. H&E whole slides from resection specimen (n = 289) were categorized according to their immune cell infiltrate as “hot,” “cold,” or “excluded.” Results: Investigating tumor immune cell patterns, we found significant differences in survival rates. Immunologic “hot” and “excluded” HNSCCs are associated with better overall survival than “cold” HNSCC patients (p < 0.05). Interestingly, the percentage of all three patterns is nearly identical in p16 positive and negative HNSCCs. Conclusions: Using a plain histological H&E approach to categorize HNSCC as being immunologic “hot,” “cold,” or “excluded” can offer a forecast of patients' prognosis and may thus aid as a potential prognostic tool in routine pathology reports. This “hot-cold-excluded” scheme needs to be applied to more HNSCC cohorts and possibly to other cancer types to determine prognostic meaning, e.g., regarding OS or DFS. Furthermore, our cohort reflects epidemiological data in the national, European, and international context. It may, therefore, be of use for future HNSCC characterization.
| Original language | English |
|---|---|
| Article number | 622330 |
| Journal | Frontiers in medicine |
| Volume | 8 |
| Pages (from-to) | 622330 |
| ISSN | 2296-858X |
| DOIs | |
| Publication status | Published - 27.01.2021 |
Funding
This research was funded by a clinical scientist fellowship of the Medical Faculty of the University of Lübeck (J26-2018) to CI. Fellowships of the Mildred Scheel doctoral program of the German Cancer Aid awarded to LK and F-OP (grant numbers 70113940 and 70112679, respectively). We thank medical technical staff Wenzel Vogel and Eva Dreyer for excellent technical support. Franz Dressler provided us with highly appreciated statistical advice. Funding. This research was funded by a clinical scientist fellowship of the Medical Faculty of the University of L?beck (J26-2018) to CI. Fellowships of the Mildred Scheel doctoral program of the German Cancer Aid awarded to LK and F-OP (grant numbers 70113940 and 70112679, respectively).
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)